Choline alfoscerate

Other nervous system drugs. Parasympathomimetics

ATC code: N07AX02

Brand names – drugs: Choline alfoscerate, Gliatilin

Brand names – supplements: Double Wood Alpha GPCSupplements are not tested in clinical trials and are not registered as medications.

Updated 24 Sep 2026 · Methodology

Indications

Ischemic stroke

Adjunct

In Italy alpha-GPC is used in the recovery phase of ischemic stroke as a neuroprotectant and aid to cognitive-motor recovery. The evidence base includes several Italian RCTs of small to medium power (Barbagallo 1994 and others) showing moderate MMSE and ADL improvement when given in the first 28 days after stroke at 1000 mg/day parenterally then 1200 mg/day orally. 2019 in acute ischemic stroke guidelines list tPA thrombolysis within 4.5 h, thrombectomy for large vessel occlusion, antithrombotic therapy, BP control and statins as the backbone; alpha-GPC is not mentioned in AHA. 2021 for post-stroke cognitive impairment lists rehabilitation and vascular risk factor control first-line. In Russia Gliatilin and Tsereton are in stroke care standards, but this does not raise the international evidence level. If alpha-GPC was recommended as monotherapy instead of the standard programme (BP control, statin, antiplatelet or anticoagulant by indication, rehabilitation), consider seeking a second opinion from a neurologist.

Sources

ICD-10: I63 · ICD-11: 8B11

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Mild-to-moderate depression

Not recommended

Alpha-GPC is sometimes recommended for depression in elderly patients with vascular cognitive dysfunction as «cholinergic mood support». No direct RCTs in depressive disorder: ASCEND-S and ASCOMALVA data recorded behavioural-scale changes in dementia patients, not in patients with primary depressive episode. 2022 (NG222) for mild-to-moderate depression lists CBT and SSRIs (sertraline, escitalopram, fluoxetine) first-line; alpha-GPC is not in guidelines. SEP 2014 in Spain gives the same recommendation. If alpha-GPC was recommended for depression instead of a psychiatric consultation, CBT and adequate pharmacotherapy, consider seeking a second opinion.

Sources

ICD-10: F32.0 · ICD-11: 6A70.0

Vascular dementia

Not recommended

Alpha-GPC is one of the few cholinergic precursors with relatively concrete evidence in vascular dementia, mostly from Italian centres. The Cochrane Fioravanti 2005 review of choline precursors (CDP-choline and alpha-GPC) in chronic cerebrovascular disorders showed moderate cognitive and behavioural scale improvement. The ASCEND-S 2021 RCT (n=210, Italian multicenter) in vascular cognitive impairment demonstrated a moderate effect on MMSE and ADAS-Cog at 1200 mg/day × 6 months. AEMPS has not registered the product; there is no centralised EU marketing authorisation. dementia 2018 (NG97) lists vascular risk factor control (BP, statins, antiplatelets) first-line for vascular dementia; cholinergic therapy can be considered in mixed dementia. Gliatilin and Tsereton are registered in the Russian GRLS. Prescription requires a confirmed vascular dementia diagnosis (CT/MRI, MMSE, MoCA). If isolated vascular dementia was diagnosed without considering donepezil or rivastigmine, consider seeking a second opinion from a neurologist.

Sources

ICD-10: F01 · ICD-11: 6D81

Alzheimer disease

Not recommended

Alpha-GPC is sometimes recommended in Alzheimer disease as «natural enhancement of cholinergic therapy». The Italian ASCOMALVA RCT (n≈210) tested alpha-GPC 1200 mg/day as an add-on to donepezil 10 mg/day vs donepezil + placebo in mild-to-moderate Alzheimer. Published results showed a heterogeneous effect on MMSE and ADAS-Cog, but the design is criticised for a single-centre sample and lack of independent replication. 2018 (NG97) for Alzheimer disease lists cholinesterase inhibitors (donepezil, rivastigmine, galantamine) first-line at MMSE 10–26 and memantine in severe dementia; alpha-GPC is not in guidelines. AEMPS has not registered the product; has not granted a marketing authorisation. If alpha-GPC was recommended for confirmed Alzheimer disease instead of donepezil, rivastigmine or galantamine, consider seeking a second opinion from a dementia-specialist neurologist.

Sources

ICD-10: G30 · ICD-11: 8A20

Anti-aging and longevity

Not recommended

Alpha-GPC is sold in the anti-aging segment as «natural slowing of brain aging». No evidence base: there are no RCTs with lifespan, dementia incidence or aging biomarker endpoints for alpha-GPC. has not approved any «anti-aging» health claim for choline compounds. Concerns: a post-hoc ARIC 2021 analysis (population cohort) recorded an association between long-term choline supplement use and increased ischemic stroke and atherosclerosis risk via the TMAO metabolite; the link needs RCT confirmation. If alpha-GPC is taken as part of an «anti-aging protocol» without a confirmed diagnosis and physician supervision, there is neither evidence of benefit nor long-term safety data.

Sources

Memory and concentration enhancement

Not recommended

Alpha-GPC is sold in the biohacking segment as a «natural memory and focus nootropic» for healthy adults and students. No evidence base in cognitively healthy people without a dementia diagnosis: Fioravanti 2005 and ASCEND-S 2021 RCTs were conducted in patients with already confirmed cognitive impairment, not in healthy participants. has not approved any memory or concentration health claim for choline compounds in healthy adults. NIH ODS 2024 lists adequate choline intake for adults at 425–550 mg/day from all food sources without rationale for clinical benefit from high doses. If alpha-GPC was recommended for subjective memory decline without neurological workup (MMSE, MoCA, CT/MRI when needed, depression screening, sleep check, TSH), consider seeking a second opinion.

Sources

Post-stroke cognitive impairment

Not recommended

For post-stroke cognitive impairment, choline alfoscerate lacks an evidence base by international standards. EFNS 2012 and 2014 do not recommend it as a drug with confirmed efficacy. Post-stroke rehabilitation is based on cognitive training, physical rehabilitation, vascular risk factor control and depression treatment.

Sources

ICD-10: I69.3 · ICD-11: 8B25

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Proposed mechanism: on metabolism, releases choline, which is incorporated into neuronal membrane phospholipids and used for acetylcholine synthesis in cholinergic neurons. Manufacturers position the drug as a «neuroprotective» agent with cognitive effects. Clinical efficacy by these mechanisms is not confirmed in high-quality RCTs. International dementia, post-stroke cognitive impairment and Alzheimer disease guidelines do not mention the drug.

Safety

Contraindications

Acute phase of hemorrhagic stroke (first 7 days)
Pregnancy, breastfeeding (insufficient data)
Age under 18 (insufficient data)
Hypersensitivity to drug components

Serious adverse effects

Anaphylactic reactions (rare)

Common adverse effects

Nausea
Headache
Insomnia, less often drowsiness
Agitation, anxiety

Uncommon adverse effects

Rash, pruritus
Confusion in older patients

Pregnancy: can you take Choline alfoscerate?

No FDA category assigned. The drug has no FDA approval. Safety data in pregnancy are insufficient. Not prescribed during pregnancy or breastfeeding.

Breastfeeding: can you take Choline alfoscerate?

Data on transfer into breast milk are insufficient. If treatment is necessary, breastfeeding is interrupted.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Evidence

Choline alfoscerate has no or approval. In most countries, it is not used in clinical practice. The drug remains in the registers of post-Soviet countries and Italy as a legacy of older regulatory decisions. Published RCTs have methodological limitations: small sample size, short duration, soft endpoints and manufacturer sponsorship. Before prescribing, openly discuss the limitations of the evidence base with the patient.

Alternatives

For the complaints prompting choline alfoscerate prescriptions, an evidence-based strategy includes: neuropsychological evaluation, vascular risk factor assessment, depression screening (), sleep assessment and brain MRI if structural pathology is suspected. For confirmed dementia – cholinesterase inhibitors and memantine per standards. For vascular risk factors – antihypertensives, statins and antiplatelet agents on indication.

Monitoring

Efficacy is assessed by objective cognitive scales (MMSE, MoCA) at baseline and at 3–6 months. Lack of improvement or deterioration requires strategy review. ALT/AST monitoring at least every 6 months during long-term use.

Common myths

Myth: «Gliatilin restores neurons». Fact: modern medicine cannot restore dead neurons with any drug. «Neuroprotective» effects are experimental, with no confirmed clinical outcomes.

Myth: «choline alfoscerate is useful as a 2-courses-per-year preventive». Fact: cognitive impairment prevention is based on vascular risk factor control, physical activity, Mediterranean diet, learning and social engagement. Course-based drug use without evidence is marketing.

Myth: «Gliatilin is a high-quality Italian drug». Fact: country of origin is not evidence of efficacy. The drug is not -approved and is not used in the US, UK, Germany or Canada.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Choline alfoscerate used for?

Choline alfoscerate is evaluated for the following indications with varying evidence strength: Ischemic stroke (evidence tier C), Vascular dementia (evidence tier D), Mild-to-moderate depression (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Choline alfoscerate?

Common side effects of Choline alfoscerate (≥ 1 in 100): Nausea, Headache, Insomnia, less often drowsiness, Agitation, anxiety. See the Safety section for uncommon and serious reactions.

Is Choline alfoscerate safe during pregnancy?

No FDA category assigned. The drug has no FDA approval. Safety data in pregnancy are insufficient. Not prescribed during pregnancy or breastfeeding.

Is Choline alfoscerate compatible with breastfeeding?

Data on transfer into breast milk are insufficient. If treatment is necessary, breastfeeding is interrupted.

Who should not take Choline alfoscerate?

Choline alfoscerate is contraindicated in: Acute phase of hemorrhagic stroke (first 7 days); Pregnancy, breastfeeding (insufficient data); Age under 18 (insufficient data); Hypersensitivity to drug components. Full list in the Safety section.

Gliatilin restores neurons

modern medicine cannot restore dead neurons with any drug. «Neuroprotective» effects are experimental, with no confirmed clinical outcomes.

choline alfoscerate is useful as a 2-courses-per-year preventive

cognitive impairment prevention is based on vascular risk factor control, physical activity, Mediterranean diet, learning and social engagement. Course-based drug use without evidence is marketing.

Gliatilin is a high-quality Italian drug

country of origin is not evidence of efficacy. The drug is not FDA-approved and is not used in the US, UK, Germany or Canada.

Official sources

Direct links to regulator labels. Open in a new tab.

GRLS

Other drugs in this group

Betahistine, Cinnarizine, Disulfiram, Flunarizine, Methadone, Nicotine